# Neogenomics Inc: overview

NEO · Nasdaq · CIK 1077183 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/neo.md) · [Financials](/companies/neo/financials.md) · [Filings](/companies/neo/filings.md) · [Insiders](/companies/neo/insiders.md)

Latest reported revenue: [$201.7m](/filings/0001077183-26-000059.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001077183-26-000059).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [168](/filings/0001077183-25-000175.md) | [172 d](/filings/0001077183-26-000010.md) | [168](/filings/0001077183-26-000023.md) | [181](/filings/0001077183-26-000059.md) | [188](/filings/0001077183-25-000175.md) | [190 d](/filings/0001077183-26-000010.md) | [187](/filings/0001077183-26-000023.md) | [202](/filings/0001077183-26-000059.md) |
| Gross margin | % | [44.6%](/filings/0001077183-25-000175.md) | [44.9% d](/filings/0001077183-26-000010.md) | [43.6%](/filings/0001077183-26-000023.md) | [42.6%](/filings/0001077183-26-000059.md) | [42.8%](/filings/0001077183-25-000175.md) | [43.8% d](/filings/0001077183-26-000010.md) | [43.3%](/filings/0001077183-26-000023.md) | [45.6%](/filings/0001077183-26-000059.md) |
| Operating margin | % | [(12.6%)](/filings/0001077183-25-000175.md) | [(10.7%) d](/filings/0001077183-26-000010.md) | [(16.6%)](/filings/0001077183-26-000023.md) | [(26.3%)](/filings/0001077183-26-000059.md) | [(14.4%)](/filings/0001077183-25-000175.md) | [(7.1%) d](/filings/0001077183-26-000010.md) | [(9.8%)](/filings/0001077183-26-000023.md) | [(4.8%)](/filings/0001077183-26-000059.md) |
| Net margin | % | [(10.5%)](/filings/0001077183-25-000175.md) | [(8.9%) d](/filings/0001077183-26-000010.md) | [(15.4%)](/filings/0001077183-26-000059.md) | [(24.9%)](/filings/0001077183-26-000059.md) | [(14.4%)](/filings/0001077183-25-000175.md) | [(5.2%) d](/filings/0001077183-26-000010.md) | [(9.2%)](/filings/0001077183-26-000059.md) | [1.1%](/filings/0001077183-26-000059.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(1.6) d](/filings/0001077183-25-000175.md) | [(1.8) d](/filings/0001077183-26-000010.md) | [(29.8)](/filings/0001077183-26-000023.md) | [14.0 d](/filings/0001077183-26-000059.md) | [0.6 d](/filings/0001077183-25-000175.md) | [(6.5) d](/filings/0001077183-26-000010.md) | [(13.1)](/filings/0001077183-26-000023.md) | [11.7 d](/filings/0001077183-26-000059.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [484](/filings/0001077183-24-000011.md) | [510](/filings/0001077183-25-000028.md) | [592](/filings/0001077183-26-000010.md) | [661](/filings/0001077183-26-000010.md) | [727](/filings/0001077183-26-000010.md) |
| Gross margin | % | [38.6%](/filings/0001077183-24-000011.md) | [36.9%](/filings/0001077183-25-000028.md) | [41.3%](/filings/0001077183-26-000010.md) | [43.9%](/filings/0001077183-26-000010.md) | [43.2%](/filings/0001077183-26-000010.md) |
| Operating margin | % | [(24.5%)](/filings/0001077183-24-000011.md) | [(30.9%)](/filings/0001077183-25-000028.md) | [(18.2%)](/filings/0001077183-26-000010.md) | [(13.9%)](/filings/0001077183-26-000010.md) | [(15.9%)](/filings/0001077183-26-000010.md) |
| Net margin | % | [(1.7%)](/filings/0001077183-24-000011.md) | [(28.3%)](/filings/0001077183-25-000028.md) | [(14.9%)](/filings/0001077183-26-000010.md) | [(11.9%)](/filings/0001077183-26-000010.md) | [(14.9%)](/filings/0001077183-26-000010.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(90.9)](/filings/0001077183-24-000011.md) | [(96.9)](/filings/0001077183-25-000028.md) | [(30.7)](/filings/0001077183-26-000010.md) | [(34.0)](/filings/0001077183-26-000010.md) | [(21.8)](/filings/0001077183-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/neo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $304.5m | 20,868,362 |  | Added +910,860 |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $179.2m | 12,279,523 |  | Added +2,549,545 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $147.6m | 10,113,261 |  | Added +3,950,890 |
| [Greenhouse Funds LLLP](/funds/1626220.md) | 2026-06-30 | $125.1m | 8,574,210 |  | Reduced −525,893 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $117.6m | 8,061,362 |  | Added +439,175 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $84.1m | 5,763,017 |  | Added +107,194 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $78.3m | 5,363,784 |  | Added +243,946 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $73.5m | 5,037,787 |  | Added +1,585,200 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $71.8m | 4,918,202 |  | Reduced −699,200 |
| [SCHRODER INVESTMENT MANAGEMENT GROUP](/funds/1086619.md) | 2026-06-30 | $61.9m | 4,342,883 |  | Added +774,305 |

## Recent filings

[All 1,130 filings](/companies/neo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 20:08 ET | [8-K](/filings/0001077183-26-000069.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001077183-26-000069 |
| 2026-08-11 | 20:10 ET | [8-K](/filings/0001628280-26-055697.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-055697 |
| 2026-07-28 | 20:09 ET | [10-Q](/filings/0001077183-26-000059.md) | Quarterly report, period 2026-06-30 | 0001077183-26-000059 |
| 2026-07-28 | 20:05 ET | [8-K](/filings/0001077183-26-000058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001077183-26-000058 |
| 2026-07-22 | 11:00 ET | [8-K/A](/filings/0001077183-26-000049.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001077183-26-000049 |
| 2026-07-20 | 21:27 ET | [8-K](/filings/0001077183-26-000045.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001077183-26-000045 |
| 2026-06-25 | 11:10 ET | [8-K](/filings/0001628280-26-045350.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-045350 |
| 2026-06-22 | 21:17 ET | [8-K](/filings/0001077183-26-000037.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001077183-26-000037 |
| 2026-06-17 | 10:05 ET | [8-K](/filings/0001077183-26-000031.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001077183-26-000031 |
| 2026-06-15 | 21:24 ET | [8-K](/filings/0001077183-26-000029.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001077183-26-000029 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001077183-26-000010.md), filed Feb 17, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1077183
- Tickers: NEO
- Exchange: Nasdaq
- SIC code: 8734 Services-Testing Laboratories
- State of incorporation: NV
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.